Valley National Advisers Inc. Buys 50 Shares of Thermo Fisher Scientific Inc. $TMO

Valley National Advisers Inc. boosted its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.5% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,282 shares of the medical research company’s stock after purchasing an additional 50 shares during the quarter. Valley National Advisers Inc.’s holdings in Thermo Fisher Scientific were worth $1,329,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also made changes to their positions in the company. Revolve Wealth Partners LLC increased its holdings in shares of Thermo Fisher Scientific by 4.2% in the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after acquiring an additional 20 shares during the period. Root Financial Partners LLC boosted its holdings in shares of Thermo Fisher Scientific by 5.0% in the 1st quarter. Root Financial Partners LLC now owns 506 shares of the medical research company’s stock valued at $252,000 after buying an additional 24 shares in the last quarter. Rossmore Private Capital grew its position in shares of Thermo Fisher Scientific by 0.5% in the 1st quarter. Rossmore Private Capital now owns 4,652 shares of the medical research company’s stock worth $2,315,000 after buying an additional 24 shares during the last quarter. FARMERS & MERCHANTS TRUST Co OF LONG BEACH raised its stake in shares of Thermo Fisher Scientific by 3.1% during the 2nd quarter. FARMERS & MERCHANTS TRUST Co OF LONG BEACH now owns 803 shares of the medical research company’s stock worth $326,000 after acquiring an additional 24 shares in the last quarter. Finally, ARS Wealth Advisors Group LLC boosted its stake in Thermo Fisher Scientific by 1.6% in the first quarter. ARS Wealth Advisors Group LLC now owns 1,563 shares of the medical research company’s stock valued at $778,000 after acquiring an additional 25 shares in the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the sale, the executive vice president owned 22,367 shares of the company’s stock, valued at $10,735,712.66. This trade represents a 1.76% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CAO Joseph R. Holmes sold 385 shares of the business’s stock in a transaction dated Friday, August 29th. The stock was sold at an average price of $492.63, for a total value of $189,662.55. Following the transaction, the chief accounting officer directly owned 2,319 shares of the company’s stock, valued at approximately $1,142,408.97. This represents a 14.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 30,066 shares of company stock worth $14,182,963 over the last 90 days. Corporate insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Stock Performance

NYSE:TMO opened at $543.88 on Monday. The firm has a market capitalization of $205.38 billion, a price-to-earnings ratio of 31.46, a PEG ratio of 2.95 and a beta of 0.77. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. The company’s 50-day moving average is $482.58 and its two-hundred day moving average is $446.77. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $610.97.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, beating the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The firm had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. During the same quarter last year, the firm earned $5.37 EPS. The firm’s revenue for the quarter was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 9.95%.

Analysts Set New Price Targets

Several brokerages recently issued reports on TMO. Evercore ISI reduced their target price on Thermo Fisher Scientific from $500.00 to $480.00 and set an “outperform” rating on the stock in a research report on Tuesday, July 8th. Wells Fargo & Company lowered their target price on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an “overweight” rating for the company in a research note on Thursday, July 24th. William Blair initiated coverage on shares of Thermo Fisher Scientific in a report on Monday, August 18th. They issued an “outperform” rating for the company. Scotiabank raised shares of Thermo Fisher Scientific from a “sector perform” rating to a “sector outperform” rating and set a $590.00 price objective on the stock in a report on Friday, July 11th. Finally, UBS Group lifted their price target on Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a “neutral” rating in a research report on Thursday, July 24th. Fifteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat.com, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and a consensus price target of $585.37.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.